Abstract
HFA 134a (1,1,1,2-tetrafluoroethane) is a ‘non-ozone depleting’ candidate for use as a drug propellant in multi-dose inhalers (MDIs). A means for assuring the safety of such a compound for human use is to check mat there is no excessive or unexpected accumulation in the body and selected regions. HFA 134a has been labelled with fluorine-18 and used with a highly sensitive whole-body γ-counting technique to measure the whole-body and regional absorption, distribution and retention of HFA 134a after administration in humans by single breath inhalation. In 7 healthy subjects, radiolabeled HFA 134a was mainly eliminated by ventilation during the first few minutes, with on average 7.2% of the radioactivity retained in the body at 10 min. This radioactivity cleared with an apparent terminal half-life of 1.5-4.2 h. At 5.5 h an average of < 1% of the administered dose (< 750 μg, ca 0.2 μCi) was retained in the body. The disposition of radioactivity was independent of the position of radiolabel. Hence, there was no evidence of degradative metabolism. Inhaled HFA 134a first distributed to all regions of the body and then cleared without evident accumulation in any specific region. The study supports the proposal that HFA 134a is a safe substitute for current propellants in MDIs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
United Nations Environment Programme, Nairobi. Montreal protocol on substances that deplete the ozone layer. 1987.
Dagani R. Chem Eng News 1990; 68: (36, September 3); 8.
Manzer LE. The CFC-ozone issue: Progress on the development of alternatives to CFCs. Science 1990; 249: 31–35.
Zurer PS. Chem. Eng. News 1989; 67: (30, July 24), 7–13.
Cunningham VJ, Pike VW, Bailey D, Freemantle CAJ, Page BC, Jones AKP, Kensett MJ, Bateman D, Luthra S.K, Jones T. A method of studying pharmacokinetics in man at picomolar drug concentrations. Br J Clin Pharmacology 1991; 32: 167–172.
Aigbirhio FI, Pike VW, Waters SL, Makepeace J, Tanner RJN. Efficient and selective labelling of the CFC alternative, 1,1,1,2-tetrafluoroethane, with 18F in the 1-position. J Chem Soc Chem Commun 1993; 1064–106.
Aigbirhio FI, Pike VW, Waters SL, Makepeace J, Steel CJ, Tanner RJN. Site-selective labelling of the CFC alternative, 1,1,1,2-tetrfaluoroethane, in biodistribution studies in man. J Label Compd Radiopharm 1994; 35, 171–173.
Aigbirhio FI, Pike VW, Waters SL, Tanner RJN. Efficient regioselective labelling of the CFC alternative 1,1,1,2-tetrafluoroethane (HFC 134a) with fluorine-18. J Fluorine Chem 1995; in press.
Guillaume M, Luxen A, Nebeling B, Argentini M, Clark JC, Pike VW. Recommendations for fluorine-18 production. Appl Radiat Isot 1991; 42: 749–762.
Pike VW, Waters SL, Aigbirhio FI, Makepeace J, Tanner RJN. Novel use of an isotope separator to determine the posotion of fluorine-18 in labelled 1,1,1,2-tetrafluoroethanes. J Label Compd Radiopharm 1994; 35; 120–122.
Pike VW, Waters SL, Aigbirhio FI, Makepeace J, Tanner RJN. Novel use of an isotope separator to determine the position of fluorine-18 in labelled 1,1,1,2-tetrafluoroethanes. Org Mass Spectrom 1994; 29: 499–504.
Bush F. Energy absorption in radium therapy. Br J Radiol 1946; 14: 14–21.
Olsson P, Aigbirhio FI, Freemantle CAJ, Pike VW, Page BC, Rhodes CG, Waters SL, Ventresca GP, Tanner RJN. The absorption and disposition of a non-chlorinated propellant, GR106642X (1,1,1,2-tetrafluoroethane, HFA 134a) as examined by 18F-labelling and whole body counting in healthy subjects. Presented at the American Thoracic Society National Conference, Boston, USA, May 1994. In press.
Pike VW, Aigbirhio FI, Freemantle CAJ, Page BC, Rhodes CG, Waters SL, Jones T, Olsson P, Ventresca GP, Tanner RJN, Hayes M, Hughes JMB. The disposition of inhaled 1,1,1,2-tetrafluoroethane in healthy subjects and COPD patients measured by 18F-labelling and whole-body γ-counting. Drug Metab Disp. In Press.
Reizenstein P. Methods of reducing geometry variations in whole body counting. In: Clinical whole body counting. Bristol: John Wright & Sons, 1973: 18–32, and references therein.
Denyer LH, Mallet DN, Olsson P, Robinson C. A repeat dose safety and tolerability study with GR106642X. Glaxo Group Research, Report No WMH/91/024.
Ellis MK, Gowans LA, Green T, Tanner RJN. Metabolic fate and disposition of 1,1,1,2-tetrafluoroethane (HFC 134a) in rat following a single exposure by inhalation. Xenobiotica 1993; 23: 719–729.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Pike, V.W. et al. (1995). The Disposition of a New Drug Propellant (HFA 134a) in Humans Studied by Fluorine-18 Labelling and Whole-Body γ-Counting. In: Comar, D. (eds) PET for Drug Development and Evaluation. Developments in Nuclear Medicine, vol 26. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0429-6_30
Download citation
DOI: https://doi.org/10.1007/978-94-011-0429-6_30
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4191-1
Online ISBN: 978-94-011-0429-6
eBook Packages: Springer Book Archive